Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 1Central Nervous System Diseases 1Brain Neoplasms 1

Interventions

gadobenic acid 2XENP 1595 2Cancer Vaccines 2Adjuvants, Immunologic 2veliparib 1interferon gamma-1b 1glutathione pegylated liposomal doxorubicin 1gadoteridol 1elacestrant 1abemaciclib 1Trastuzumab 1Temozolomide 1RAD1901 1Oncolytic Virotherapy 1Interferon-gamma 1Immunotherapy 1Craniotomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Central Nervous System Diseases × Craniotomy × Clear all
NCT00805376 2018-07-16

DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas

DNAtrix, Inc.

Phase 1 Completed
37 enrolled
CNS

Brain Neoplasms, Central Nervous System Diseases, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡